Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003

被引：0
|
作者：
Goldschmidt, Hartmut
Dimopoulos, Meletios A.
Weisel, Katja C.
Moreau, Philippe
Lacy, Martha
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Banos, Anne
Rocafiguera, Albert Oriol
Yu, Xin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
San-Miguel, Jesus F.
机构：
[1] Univ Klinikum Heidelberg, Heidelberg, Germany
[2] Alexandra Hosp, Athens, Greece
[3] Univ Tubingen Hosp, Dept Med, Tubingen, Germany
[4] Hop Hotel Dieu, Univ Hosp, Nantes, France
[5] Mayo Clin, Rochester, MN USA
[6] Vancouver Gen Hosp, Vancouver, BC, Canada
[7] Katholieke Univ Leuven Hosp, Dept Hematol, Louvain, Belgium
[8] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Pierre Benite, France
[9] Ctr Hosp Cote Basque, Bayonne, France
[10] HGTiP, Inst Catala Oncol, Barcelona, Spain
[11] Celgene Corp, Summit, NJ USA
[12] Hosp Univ Salamanca, Salamanca, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8528
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI)
    Weisel, Katja C.
    Dimopoulos, Meletios A.
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Rocafiguera, Albert Oriol
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    San-Miguel, Jesus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] ADVERSE EVENTS AND MANAGEMENT IN MM-003, A PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (POM plus LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Delforge, M.
    Dimopoulos, M.
    Weisel, K.
    Moreau, P.
    Lacy, M.
    Song, K.
    Karlin, L.
    Goldschmidt, H.
    Banos, A.
    Oriol, A.
    Alegre, A.
    Chen, C.
    Cavo, M.
    Garderet, L.
    Ivanova, V.
    Martinez-Lopez, J.
    Yu, X.
    Sternas, L.
    Jacques, C.
    Zaki, M.
    Miguel, J.
    HAEMATOLOGICA, 2013, 98 : 329 - 330
  • [3] ANALYSIS OF MM-003 PATIENTS WITH MODERATE RENAL IMPAIRMENT USING POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (POM plus LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Weisel, K.
    Dimopoulos, M.
    Moreau, P.
    Lacy, M.
    Song, K.
    Delforge, M.
    Karlin, L.
    Goldschmidt, H.
    Banos, A.
    Oriol, A.
    Alegre, A.
    Chen, C.
    Cavo, M.
    Garderet, L.
    Ivanova, V.
    Martinez-Lopez, J.
    Yu, X.
    Sternas, L.
    Jacques, C.
    Zaki, M.
    San Miguel, J.
    HAEMATOLOGICA, 2013, 98 : 105 - 105
  • [4] MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM)
    San-Miguel, Jesus F.
    Weisel, Katja C.
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Rocafiguera, Albert Oriol
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for Res crossover.
    Morgan, Gareth J.
    San Miguel, Jesus
    Dhanasiri, Sujith
    Lee, Dawn
    Palumbo, Antonio
    Facon, Thierry
    Zaki, Mohamed H.
    Yu, Xin
    Sternas, Lars Axel
    Jacques, Christian
    Weisel, Katja C.
    Offner, Fritz
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Patient Outcomes By Prior Therapies and Depth of Response: Analysis of MM-003, a Phase 3 Study Comparing Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
    San Miguel, Jesus F.
    Weisel, Katja
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Moreau, Philippe
    Banos, Anne
    Oriol, Albert
    Garderet, Laurent
    Cavo, Michele
    Ivanova, Valentina
    Alegre, Adrian
    Martinez-Lopez, Joaquin
    Chen, Christine I.
    Renner, Christoph
    Bahlis, Nizar J.
    Yu, Xin
    Teasdale, Terri
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    BLOOD, 2013, 122 (21)
  • [7] Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003
    Song, Kevin W.
    Dimopoulos, Meletios A.
    Weisel, Katja C.
    Moreau, Philippe
    Lacy, Martha
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Banos, Anne
    Rocafiguera, Albert Oriol
    Hudgens, Stacie
    Yu, Zhinuan
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    San-Miguel, Jesus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios A.
    Weisel, Katja
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Moreau, Philippe
    Banos, Anne
    Oriol, Albert
    Garderet, Laurent
    Cavo, Michele
    Ivanova, Valentina
    Alegre, Adrian
    Lopez, Joaquin Martinez
    Chen, Christine I.
    Spencer, Andrew
    Knop, Stefan
    Bahlis, Nizar J.
    Renner, Christoph
    Yu, Xin
    Hong, Kevin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    San Miguel, Jesus F.
    BLOOD, 2013, 122 (21)
  • [9] Analyzing the relationship of response and survival in patients with refractory or relapsed and refractory multiple myeloma (RRMM) treated with pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in the MM-003 trial.
    Weisel, Katja
    Moreau, Philippe
    Gibson, Craig J.
    Song, Kevin W.
    Saunders, Owain
    Sternas, Lars Axel
    Hong, Kevin
    Zaki, Mohamed H.
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial
    Song, Kevin W.
    Dimopoulos, Meletios A.
    Weisel, Katja
    Delforge, Michel
    Karlin, Lionel
    Goldschmidt, Hartmut
    Moreau, Philippe
    Banos, Anne
    Oriol, Albert
    Spencer, Andrew
    Knop, Stefan
    Renner, Christoph
    Bahlis, Nizar J.
    Amatya, Ramesh
    Yu, Xin
    Monzini, Mara Silvia
    Sternas, Lars
    Zaki, Mohamed H.
    Jacques, Christian J.
    San Miguel, Jesus F.
    BLOOD, 2013, 122 (21)
12345